Your session is about to expire
← Back to Search
Combination Chemotherapy for Pancreatic Cancer
Study Summary
This trial is testing gemcitabine, dasatinib, and erlotinib to treat pancreatic cancer. The goal is to find the best dose with the least side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking strong drugs that affect liver enzyme CYP3A4.It's been over 4 weeks since my last radiation dose, and I have measurable cancer outside the treated area.I haven't had chemotherapy or radiotherapy in the last 4-6 weeks and have recovered from any side effects.I am not pregnant and will stop breastfeeding if treated with erlotinib or dasatinib.I have cancer that has spread to my brain.Your white blood cell count is at least 3,000 per microliter.Your blood platelet count is at least 100,000 per microliter.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.You have enough infection-fighting white blood cells in your body.My kidney function, measured by creatinine levels or clearance, is normal or near normal.I do not have conditions affecting my body's ability to absorb nutrients.I do not have any active cancer except for treated skin cancer.I am fully active and can carry on all pre-disease activities without restriction.I am HIV positive and on combination antiretroviral therapy.I don't have serious heart issues like recent heart attacks or abnormal heart rhythms.My pancreatic cancer cannot be removed by surgery and is not an islet cell or ampullary tumor.I've had chemotherapy for advanced disease but not with gemcitabine, or it's been over 6 months since my last dose of gemcitabine, and I've recovered from the side effects.I can swallow pills.I have not had major surgery in the last 4 weeks.You have a tumor that can be measured using specific guidelines for assessing tumor size.Your liver enzymes (AST and ALT) are not too high, unless you have liver metastases, in which case they can be a little higher.I am allergic to drugs similar to dasatinib, erlotinib, or gemcitabine.Your total bilirubin level should be less than 2.5 times the normal limit at the medical center.
- Group 1: Treatment (gemcitabine, dasatinib, erlotinib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is enrollment currently open for this research study?
"Unfortunately, the study is not currently recruiting patients. It was initially posted on July 30th 2012 and last updated June 28 2022. For those seeking alternative clinical trials there are 2,993 studies actively enlisting participants with carcinoma and 548 trials for Gemcitabine Hydrochloride accepting new enrollees."
Could you provide a history of research conducted with Gemcitabine Hydrochloride?
"Currently, Gemcitabine Hydrochloride is the focus of 548 active medical trials with 147 in Phase 3. In particular, there are 31585 sites globally that are administering this medication and a good portion of them are located in Adelaide, South Australia."
What safety considerations should be taken into account when administering Gemcitabine Hydrochloride?
"Our team at Power believes that Gemcitabine Hydrochloride is relatively safe, given its Phase 1 status. However, there is limited safety data available to support this conclusion."
To what medical ailments is Gemcitabine Hydrochloride commonly administered?
"Gemcitabine Hydrochloride is traditionally used to treat leukemia, but has also been found helpful in combating urinary bladder cancer, small cell lung carcinoma (sclc), and head and neck carcinomas."
How many people have been enlisted in this trial thus far?
"At the present time, this clinical trial is not open to recruitment. It was first posted on July 30th 2012 and last updated June 28th 2022. For those exploring other studies, there are 2999 carcinoma related trials in search of patients as well as 548 actively accepting participants for a Gemcitabine Hydrochloride study."
Share this study with friends
Copy Link
Messenger